Access to innovative cancer medicines in a middle-income country - the case of Mexico
Background Cancer has become the third cause of death in Mexico. Treatment for cancer is often complex and lengthy. New and better medicines enter the market at high prices, which may limit access. Like most Latin American countries, Mexico has an essential cancer medicines list that includes innova...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1186/s40545-018-0153-y |
| _version_ | 1797401379248013312 |
|---|---|
| author | Daniela Moye-Holz Rene Soria Saucedo Jitse P van Dijk Sijmen A Reijneveld Hans V Hogerzeil |
| author_facet | Daniela Moye-Holz Rene Soria Saucedo Jitse P van Dijk Sijmen A Reijneveld Hans V Hogerzeil |
| author_sort | Daniela Moye-Holz |
| collection | DOAJ |
| description | Background Cancer has become the third cause of death in Mexico. Treatment for cancer is often complex and lengthy. New and better medicines enter the market at high prices, which may limit access. Like most Latin American countries, Mexico has an essential cancer medicines list that includes innovative medicines. Their accessibility and use in the public sector remains unknown. Therefore, we describe the use, as a proxy of access, of innovative and essential cancer medicines in the public sector in Mexico, by insurance institution, and by five regions between 2010 to 2016. Methods We used drug utilization research methods to assess the use of eight patented cancer medicines. Through the national transparency platform, we obtained data on the quantities of these medicines used in all public health facilities and social health insurance institutions and recalculated those figures into defined daily dose (DDD) per 1000 population per year. Results Overall, the use of all medicines increased over the years, especially for trastuzumab, rituximab and imatinib. The use of innovative medicines was higher per population covered in social health insurance institutions than in governmental facilities. Throughout the study period, the Central region (including Mexico City) has used more medicines per population than the other regions. Conclusions The use and access of some essential innovative cancer medicines has increased over the years, but remains unequal across insurance schemes and regions. Particularly, the Ministry of Health Insurance scheme and Northern and Western regions in the country would benefit from additional efforts to increase access to essential cancer medicines. |
| first_indexed | 2024-03-09T02:08:00Z |
| format | Article |
| id | doaj.art-c8c88c847b7f450e9d7439cc87c5da39 |
| institution | Directory Open Access Journal |
| issn | 2052-3211 |
| language | English |
| last_indexed | 2024-03-09T02:08:00Z |
| publishDate | 2018-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj.art-c8c88c847b7f450e9d7439cc87c5da392023-12-07T15:28:01ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112018-12-0111110.1186/s40545-018-0153-y12315083Access to innovative cancer medicines in a middle-income country - the case of MexicoDaniela Moye-Holz0Rene Soria Saucedo1Jitse P van Dijk2Sijmen A Reijneveld3Hans V Hogerzeil4Department of Community and Occupational Medicine, University Medical Center Groningen,Boston University School of Public Health,Department of Community and Occupational Medicine, University Medical Center Groningen,Department of Community and Occupational Medicine, University Medical Center Groningen,Department of Community and Occupational Medicine, University Medical Center Groningen,Background Cancer has become the third cause of death in Mexico. Treatment for cancer is often complex and lengthy. New and better medicines enter the market at high prices, which may limit access. Like most Latin American countries, Mexico has an essential cancer medicines list that includes innovative medicines. Their accessibility and use in the public sector remains unknown. Therefore, we describe the use, as a proxy of access, of innovative and essential cancer medicines in the public sector in Mexico, by insurance institution, and by five regions between 2010 to 2016. Methods We used drug utilization research methods to assess the use of eight patented cancer medicines. Through the national transparency platform, we obtained data on the quantities of these medicines used in all public health facilities and social health insurance institutions and recalculated those figures into defined daily dose (DDD) per 1000 population per year. Results Overall, the use of all medicines increased over the years, especially for trastuzumab, rituximab and imatinib. The use of innovative medicines was higher per population covered in social health insurance institutions than in governmental facilities. Throughout the study period, the Central region (including Mexico City) has used more medicines per population than the other regions. Conclusions The use and access of some essential innovative cancer medicines has increased over the years, but remains unequal across insurance schemes and regions. Particularly, the Ministry of Health Insurance scheme and Northern and Western regions in the country would benefit from additional efforts to increase access to essential cancer medicines.http://dx.doi.org/10.1186/s40545-018-0153-yaccessdrug utilizationessential cancer medicinesmexicoinsurance schemes accessregional access |
| spellingShingle | Daniela Moye-Holz Rene Soria Saucedo Jitse P van Dijk Sijmen A Reijneveld Hans V Hogerzeil Access to innovative cancer medicines in a middle-income country - the case of Mexico Journal of Pharmaceutical Policy and Practice access drug utilization essential cancer medicines mexico insurance schemes access regional access |
| title | Access to innovative cancer medicines in a middle-income country - the case of Mexico |
| title_full | Access to innovative cancer medicines in a middle-income country - the case of Mexico |
| title_fullStr | Access to innovative cancer medicines in a middle-income country - the case of Mexico |
| title_full_unstemmed | Access to innovative cancer medicines in a middle-income country - the case of Mexico |
| title_short | Access to innovative cancer medicines in a middle-income country - the case of Mexico |
| title_sort | access to innovative cancer medicines in a middle income country the case of mexico |
| topic | access drug utilization essential cancer medicines mexico insurance schemes access regional access |
| url | http://dx.doi.org/10.1186/s40545-018-0153-y |
| work_keys_str_mv | AT danielamoyeholz accesstoinnovativecancermedicinesinamiddleincomecountrythecaseofmexico AT renesoriasaucedo accesstoinnovativecancermedicinesinamiddleincomecountrythecaseofmexico AT jitsepvandijk accesstoinnovativecancermedicinesinamiddleincomecountrythecaseofmexico AT sijmenareijneveld accesstoinnovativecancermedicinesinamiddleincomecountrythecaseofmexico AT hansvhogerzeil accesstoinnovativecancermedicinesinamiddleincomecountrythecaseofmexico |